il17a  (R&D Systems)

Journal: Science China. Life sciences

Article Title: Interleukin-17 inhibits development of malignant pleural effusion via interleukin-9-dependent mechanism.

doi: 10.1007/s11427-016-0097-y

Figure Lengend Snippet: Figure 1 Effect of IL-17 on development of malignant pleural effusions (MPE). A, Fourteen days after intrapleural injection of Lewis lung cancer cells, positron emission tomography and computed tomography imaging of developing pleural tumors and MPE in wild type (WT) mice (top panels), WT mice receiving intraperitoneal injection of anti-IL17A mAb (WT+anti-IL-17, second panels), IL-17/ mice (third panels), and IL-17/ mice receiving intraperitoneal injection of recombinant mouse IL17A (IL-17/+rmIL-17, bottom panels). B, Comparison of maximum standard- ized uptake value (SUVmax) on positron emission tomography were calcu- lated among the above four groups (each n=10). Data are presented as means±SE. *, P<0.05 compared with WT group; †, P<0.001 compared with IL-17/ group, the comparisons were determined by one-way ANOVA.

Article Snippet: The cell pellets of MPE, blood, and spleen were resuspended in PBS, and mononuclear cells were isolated by Ficoll-Hypaque gradient centrifugation (Pharmacia, Sweden) to determine T cell subsets within 1 h. In vivo treatment of mice At days 1, 3, 6, 9, and 12 after intrapleural instillation of LLC cells, WT mice (n=10) received intraperitoneal injection of 100 μg anti-IL17A neutralizing mAb (clone eBioMM17F3, eBioscience, lgG1, USA) or 100 μg mouse IgG1 isotype control mAb (eBioscience); while IL-17/ mice were injected intraperitoneally at a dose of 1 μg recombinant mouse (rm) IL17A diluted in PBS containing 0.1% albumin (R&D System, USA) or PBS containing 0.1% albumin in a total volume of 100 μL.

Techniques: Injection, Positron Emission Tomography, Computed Tomography, Imaging, Recombinant, Comparison

Journal: Science China. Life sciences

Article Title: Interleukin-17 inhibits development of malignant pleural effusion via interleukin-9-dependent mechanism.

doi: 10.1007/s11427-016-0097-y

Figure Lengend Snippet: Figure 2 Effect of IL-17 on expression of CD34 and Ki-67 in pleural malignant tumor tissues. Tumor tissues were harvested from wild type (WT), WT mice receiving intraperitoneal injection of anti-IL17 mAb (WT+anti-IL-17), IL-17/ mice, and IL-17/ mice receiving intraperitoneal injection of recombinant mouse IL17A (IL-17/+rmIL-17), the paraffin sections were stained with Abs specific to CD34 and Ki-67, 4′,6-diamidino-2-phenylindole mounting medium was used for cell nuclei staining. Comparisons of CD34+ cells (A) and Ki-67+ cells (B) among the above four groups (each n=5) are shown. Data are presented as means±SE. *, P<0.01 compared with WT group; †, P<0.01 compared with IL-17/ group, the comparisons were determined by one-way ANOVA.

Article Snippet: The cell pellets of MPE, blood, and spleen were resuspended in PBS, and mononuclear cells were isolated by Ficoll-Hypaque gradient centrifugation (Pharmacia, Sweden) to determine T cell subsets within 1 h. In vivo treatment of mice At days 1, 3, 6, 9, and 12 after intrapleural instillation of LLC cells, WT mice (n=10) received intraperitoneal injection of 100 μg anti-IL17A neutralizing mAb (clone eBioMM17F3, eBioscience, lgG1, USA) or 100 μg mouse IgG1 isotype control mAb (eBioscience); while IL-17/ mice were injected intraperitoneally at a dose of 1 μg recombinant mouse (rm) IL17A diluted in PBS containing 0.1% albumin (R&D System, USA) or PBS containing 0.1% albumin in a total volume of 100 μL.

Techniques: Expressing, Injection, Recombinant, Staining

Journal: Science China. Life sciences

Article Title: Interleukin-17 inhibits development of malignant pleural effusion via interleukin-9-dependent mechanism.

doi: 10.1007/s11427-016-0097-y

Figure Lengend Snippet: Figure 3 Effect of IL-17 on distributions of Th9 and Th2 cells in malignant pleural effusions (MPE), blood and spleen. A, The representative flow cy- tometric dot plots of Th9 and Th2 cells in wild type (WT) mice (top panels), WT mice receiving intraperitoneal injection of anti-IL17 mAb (WT+anti-IL-17, second panels), IL-17/ mice (third panels), and IL-17/ mice receiving intraperitoneal injection of recombinant mouse IL17 (IL-17/+rmIL-17, bottom panels). Comparisons of percentages of Th9 (B) and Th2 cells (C) in MPE, blood and spleen from the above four groups (each n=10). Data are presented as means±SE. *, P<0.01 compared with blood and spleen, the comparisons were determined by two-way ANOVA. †, P<0.001 compared WT mice; ‡, P<0.001 compared with IL-17/ mice, the comparisons were determined by one-way ANOVA.

Article Snippet: The cell pellets of MPE, blood, and spleen were resuspended in PBS, and mononuclear cells were isolated by Ficoll-Hypaque gradient centrifugation (Pharmacia, Sweden) to determine T cell subsets within 1 h. In vivo treatment of mice At days 1, 3, 6, 9, and 12 after intrapleural instillation of LLC cells, WT mice (n=10) received intraperitoneal injection of 100 μg anti-IL17A neutralizing mAb (clone eBioMM17F3, eBioscience, lgG1, USA) or 100 μg mouse IgG1 isotype control mAb (eBioscience); while IL-17/ mice were injected intraperitoneally at a dose of 1 μg recombinant mouse (rm) IL17A diluted in PBS containing 0.1% albumin (R&D System, USA) or PBS containing 0.1% albumin in a total volume of 100 μL.

Techniques: Injection, Recombinant

Journal: Science China. Life sciences

Article Title: Interleukin-17 inhibits development of malignant pleural effusion via interleukin-9-dependent mechanism.

doi: 10.1007/s11427-016-0097-y

Figure Lengend Snippet: Figure 4 mRNA expression of IL-9 and IL-4 and their corresponding transcription factors in malignant pleural effusions (MPE). The mononuclear cells were isolated from MPE of wild type (WT) mice (top panels), WT mice receiving intraperitoneal injection of anti-IL17 mAb (WT+anti-IL-17, second pan- els), IL-17/ mice (third panels), and IL-17/ mice receiving intraperitoneal injection of recombinant mouse IL17 (IL-17/+rmIL-17, bottom panels). RNA was isolated, and qPCR was performed for il9 mRNA (A), il4 mRNA (B), irf4 mRNA (C), and gata3 mRNA (D). Electrophoresis’ photographs are representa- tives of four independent experiments. Data are presented as mean±SE of four experiments. *, P<0.01 compared with WT mice; †, P<0.01 compared with IL-17/ mice, the comparisons were determined by one-way ANOVA.

Article Snippet: The cell pellets of MPE, blood, and spleen were resuspended in PBS, and mononuclear cells were isolated by Ficoll-Hypaque gradient centrifugation (Pharmacia, Sweden) to determine T cell subsets within 1 h. In vivo treatment of mice At days 1, 3, 6, 9, and 12 after intrapleural instillation of LLC cells, WT mice (n=10) received intraperitoneal injection of 100 μg anti-IL17A neutralizing mAb (clone eBioMM17F3, eBioscience, lgG1, USA) or 100 μg mouse IgG1 isotype control mAb (eBioscience); while IL-17/ mice were injected intraperitoneally at a dose of 1 μg recombinant mouse (rm) IL17A diluted in PBS containing 0.1% albumin (R&D System, USA) or PBS containing 0.1% albumin in a total volume of 100 μL.

Techniques: Expressing, Isolation, Injection, Recombinant, Electrophoresis, Mouse Assay